3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
27
Phase 2
2
Phase 1/2
2
Phase EARLY_PHASE1
1
Phase 3
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Motor Activity
9
Breast Neoplasms
7
Neoplasms
4
Fatigue
3
Recurrence
2
Body Weight
2
Weight Loss
1
Warts
1
Vomiting
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Nausea
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia
1
Insulin Resistance
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Dementia
1
Colonic Neoplasms
1
Cognitive Dysfunction
1
Asthenia
1
Anomia
1
Alzheimer Disease
1
Interventions
Prednisone
53
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
28
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
18
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
17
Radiation
15
abiraterone
14
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
9
Radiosurgery
9
cabazitaxel
8
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
Exercise
×
Clear all
NCT00658229
2012-10-15
PEPC
Oslo University Hospital
Phase 3
Completed
60 enrolled